Loading...

Forty Seven

DB:4C8
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4C8
DB
$563M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
  • Forty Seven has significant price volatility in the past 3 months.
4C8 Share Price and Events
7 Day Returns
1.2%
DB:4C8
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
DB:4C8
-10.2%
DE Biotechs
-6%
DE Market
4C8 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Forty Seven (4C8) 1.2% 6.6% 30.6% - - -
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • No trading data on 4C8.
  • No trading data on 4C8.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

4C8 Value

 Is Forty Seven undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Forty Seven. This is due to cash flow or dividend data being unavailable. The share price is €16.31.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Forty Seven's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Forty Seven's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:4C8 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.75
NasdaqGS:FTSV Share Price ** NasdaqGS (2019-04-18) in USD $18
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Forty Seven.

DB:4C8 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:FTSV Share Price ÷ EPS (both in USD)

= 18 ÷ -3.75

-4.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Forty Seven is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Forty Seven is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Forty Seven's expected growth come at a high price?
Raw Data
DB:4C8 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
33.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Forty Seven, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Forty Seven's assets?
Raw Data
DB:4C8 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.29
NasdaqGS:FTSV Share Price * NasdaqGS (2019-04-18) in USD $18
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:4C8 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:FTSV Share Price ÷ Book Value per Share (both in USD)

= 18 ÷ 4.29

4.2x

* Primary Listing of Forty Seven.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Forty Seven is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Forty Seven's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Forty Seven has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

4C8 Future Performance

 How is Forty Seven expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
33.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Forty Seven expected to grow at an attractive rate?
  • Forty Seven's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Forty Seven's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Forty Seven's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:4C8 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:4C8 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 33.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:4C8 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:4C8 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 407 196 3
2022-12-31 219 93 3
2021-12-31 96 -78 -96 3
2020-12-31 0 -102 -108 5
2019-12-31 0 -85 -95 6
DB:4C8 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -66 -70
2018-09-30 -61 -65
2018-06-30 -49 -55
2018-03-31 -44 -49
2017-12-31 -37 -45
2016-12-31 -22 -20

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Forty Seven's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Forty Seven is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:4C8 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Forty Seven Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4C8 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 4.31 4.31 4.31 1.00
2022-12-31 2.10 2.10 2.10 1.00
2021-12-31 -2.26 -2.06 -2.57 3.00
2020-12-31 -2.77 -2.53 -2.90 4.00
2019-12-31 -2.91 -2.79 -3.19 4.00
DB:4C8 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.75
2018-09-30 -5.19
2018-06-30 -8.31
2018-03-31 -7.47
2017-12-31 -6.94
2016-12-31 -3.15

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Forty Seven will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Forty Seven's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Forty Seven has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

4C8 Past Performance

  How has Forty Seven performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Forty Seven's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Forty Seven does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Forty Seven's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Forty Seven's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Forty Seven's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Forty Seven Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4C8 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -70.37 15.43 56.67
2018-09-30 -65.49 14.21 52.70
2018-06-30 -54.66 11.88 43.55
2018-03-31 -48.77 10.21 39.15
2017-12-31 -44.90 8.13 37.17
2016-12-31 -19.54 5.15 14.46

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Forty Seven has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Forty Seven has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Forty Seven improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Forty Seven's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Forty Seven has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

4C8 Health

 How is Forty Seven's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Forty Seven's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Forty Seven is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Forty Seven's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Forty Seven's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 300.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Forty Seven Company Filings, last reported 3 months ago.

DB:4C8 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 133.22 0.49 139.02
2018-09-30 149.24 0.52 154.02
2018-06-30 53.27 0.55 58.01
2018-03-31 69.10 0.58 78.43
2017-12-31 83.46 0.61 88.11
2016-12-31 12.23 0.70 9.74
  • Forty Seven's level of debt (0.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Forty Seven's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Forty Seven has sufficient cash runway for 2.1 years based on current free cash flow.
  • Forty Seven has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 46.9% each year.
X
Financial health checks
We assess Forty Seven's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Forty Seven has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

4C8 Dividends

 What is Forty Seven's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Forty Seven dividends.
If you bought €2,000 of Forty Seven shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Forty Seven's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Forty Seven's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:4C8 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:4C8 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Forty Seven has not reported any payouts.
  • Unable to verify if Forty Seven's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Forty Seven's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Forty Seven has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Forty Seven's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Forty Seven afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Forty Seven has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

4C8 Management

 What is the CEO of Forty Seven's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark McCamish
COMPENSATION $3,677,401
AGE 65
TENURE AS CEO 1.9 years
CEO Bio

Dr. Mark A. McCamish, M.D., Ph.D., has been Chief Executive Officer, Director and President at Forty Seven Inc. since May 1, 2017. Mr. McCamish served as the Global Head of Biopharmaceutical Development at Sandoz International, a Division of Novartis. Mr. McCamish served as Head of Global Development Biopharmaceuticals & Oncology Injectables at Sandoz Inc. Dr. McCamish served as Chief Medical Officer and Senior Vice President of AbbVie Biotherapeutics Inc. (Also known as Facet Biotech Corporation). since December 2008. He served as a Senior Vice President and Chief Medical officer of PDL BioPharma Inc., from February 21, 2007 to December 2008. He has over 25 years of experience in corporate management, clinical and pharmaceutical research and academics. Dr. McCamish served as Vice President of Clinical Development at Perlegen Sciences Inc. from August 2003 to February 2007 and served as its Chief Medical Officer from September 2003 to February 2007. From January 1998 to September 2003, he served at Amgen, Inc., as a Global Development Leader and was responsible for the clinical development of Amgen's Aranesp® product in new indications. He serves as a Director of Trigemina, Inc. He served as Medical Director of Abbott Laboratories. From 1990 to 1997, he served as a Director at Abbott Laboratories. Dr. McCamish also served as a Member of Amgen's International Clinical Oversight Group responsible for approval of all clinical research protocols, clinical study reports and FDA/Regulatory submissions. Dr. McCamish served positions as a professor of Surgery at Michigan State University from 1980-1983, Internal Medicine at the University of California at Davis from 1987-1990 and Endocrinology at The Ohio State University from 1990-1997. He is a Board Certified in Internal Medicine and Nutrition & Metabolism. Dr. McCamish holds a B.S. in Physical Education and an M.S. in Ergonomics from the University of California at Santa Barbara, a Ph.D. in Human Nutrition from The Pennsylvania State University and an M.D. from the University of California at Los Angeles.

CEO Compensation
  • Insufficient data for Mark to compare compensation growth.
  • Mark's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Forty Seven management team in years:

2.5
Average Tenure
55
Average Age
  • The tenure for the Forty Seven management team is about average.
Management Team

Mark McCamish

TITLE
President
COMPENSATION
$4M
AGE
65
TENURE
1.9 yrs

Craig Gibbs

TITLE
Chief Business Officer
COMPENSATION
$550K
AGE
55
TENURE
3.6 yrs

Chris Takimoto

TITLE
Chief Medical Officer
COMPENSATION
$716K
AGE
59
TENURE
3.2 yrs

Mark Chao

TITLE
Founder & VP of Clinical Development

Jens-Peter Volkmer

TITLE
Founder and VP of Research & Early Development

Ann Rhoads

TITLE
Chief Financial Officer
AGE
53
TENURE
1 yrs

Kyle Elrod

TITLE
Senior Vice President of Planning & Operations
AGE
51

Norm Kruse

TITLE
Chief Patent Counsel

Eric Jensen

TITLE
Secretary
Board of Directors Tenure

Average tenure and age of the Forty Seven board of directors in years:

1.2
Average Tenure
58
Average Age
  • The average tenure for the Forty Seven board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mark McCamish

TITLE
President
COMPENSATION
$4M
AGE
65
TENURE
1.9 yrs

Jeff Bird

TITLE
Lead Director
AGE
57

Kristine Ball

TITLE
Director
AGE
46
TENURE
1.2 yrs

Dennis Henner

TITLE
Director
AGE
67
TENURE
3.4 yrs

Ravindra Majeti

TITLE
Director
AGE
45
TENURE
3.9 yrs

Irv Weissman

TITLE
Director
AGE
78
TENURE
3.9 yrs

Ian Clark

TITLE
Director
AGE
58
TENURE
1 yrs

Jim Allison

TITLE
Member of Scientific Advisory Board
TENURE
0.5 yrs

Pam Sharma

TITLE
Member of Scientific Advisory Board
TENURE
0.5 yrs

Ron Levy

TITLE
Member of Scientific Advisory Board
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
24. Aug 18 Buy Mhatre Investments Lp - Fund 1 Company 22. Aug 18 23. Aug 18 66,743 €13.19 €869,328
20. Aug 18 Buy Lightspeed Venture Partners Company 16. Aug 18 16. Aug 18 66,542 €13.19 €877,712
03. Jul 18 Buy Michael Speiser Individual 02. Jul 18 02. Jul 18 5,745 €13.79 €79,244
24. Aug 18 Buy Ravi Mhatre Individual 22. Aug 18 23. Aug 18 100,115 €13.19 €1,303,999
20. Aug 18 Buy Peter Nieh Individual 16. Aug 18 17. Aug 18 67,500 €13.31 €898,011
03. Jul 18 Buy James White Individual 02. Jul 18 02. Jul 18 7,415 €13.79 €102,280
03. Jul 18 Buy Jeffrey Bird Individual 02. Jul 18 02. Jul 18 4,252 €13.79 €58,650
03. Jul 18 Buy Sutter Hill Ventures Company 02. Jul 18 02. Jul 18 134,735 €13.79 €1,858,481
03. Jul 18 Buy Samuel Pullara Individual 02. Jul 18 02. Jul 18 2,059 €13.79 €28,401
03. Jul 18 Buy Stefan Dyckerhoff Individual 02. Jul 18 02. Jul 18 1,915 €13.79 €26,415
03. Jul 18 Buy Tench Coxe Individual 02. Jul 18 02. Jul 18 18,314 €13.79 €252,616
02. Jul 18 Buy Clarus Ventures, LLC Company 02. Jul 18 02. Jul 18 200,000 €13.79 €2,758,720
02. Jul 18 Buy Lightspeed Venture Partners Company 02. Jul 18 02. Jul 18 468,750 €13.79 €6,465,750
X
Management checks
We assess Forty Seven's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Forty Seven has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

4C8 News

Simply Wall St News

4C8 Company Info

Description

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Details
Name: Forty Seven, Inc.
4C8
Exchange: DB
Founded: 2014
$499,962,836
31,271,913
Website: http://www.fortyseveninc.com
Address: Forty Seven, Inc.
1490 O’Brien Drive,
Suite A,
Menlo Park,
California, 94025,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS FTSV Common Stock Nasdaq Global Select US USD 28. Jun 2018
DB 4C8 Common Stock Deutsche Boerse AG DE EUR 28. Jun 2018
MUN 4C8 Common Stock Boerse Muenchen DE EUR 28. Jun 2018
Number of employees
Current staff
Staff numbers
57
Forty Seven employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 22:52
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.